Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
Abstract Background Lung cancer is the leading cause of cancer death worldwide. With the growing number of targeted therapies and the introduction of immuno-oncology (IO), personalized medicine has become standard of care in patients with metastatic disease. The development of predictive and prognos...
Guardado en:
Autores principales: | Guus R. M. van den Heuvel, Leonie I. Kroeze, Marjolijn J. L. Ligtenberg, Katrien Grünberg, Erik A. M. Jansen, Daniel von Rhein, Richarda M. de Voer, Michel M. van den Heuvel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ae1a0ade6c6e4ed78175927614767cf1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes
por: Zedong Jiang, et al.
Publicado: (2021) -
Mutational signatures among young-onset testicular cancers
por: Nicole E. Mealey, et al.
Publicado: (2021) -
Application of Next-generation Sequencing Detecting Gene Mutation in Myelodysplastic Syndromes: Current Situation and Problems
por: XIAO Zhijian
Publicado: (2021) -
A mixture model for signature discovery from sparse mutation data
por: Itay Sason, et al.
Publicado: (2021) -
Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation
por: Jia X, et al.
Publicado: (2021)